IMGN853 With Carboplatin in Second-line Treatment of FRa Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Active:	Yes
Cancer Type:	Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer Unknown Primary	NCT ID:	NCT05456685
Trial Phases:	Phase II	Protocol IDs:	IMGN853-0420 (primary) NCI-2022-09869 2022-002034-14
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	ImmunoGen Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT05456685

Summary

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab
soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or
fallopian tube cancer following 1 prior line of platinum-based chemotherapy.

Objectives

This Phase 2 study is designed to evaluate the efficacy and safety of MIRV in combination
with carboplatin followed by MIRV continuation in FRa-positive patients with recurrent
platinum-sensitive ovarian cancer (PSOC) following 1 prior line of platinum-based
chemotherapy. Upon completion of carboplatin plus MIRV combination chemotherapy (6 cycles),
patients without progressive disease will continue on single-agent MIRV. Patients must have
confirmation of FRa positivity by the Ventana FOLR1 Assay.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.